Drug Profile
Research programme: inflammatory bowel disease therapeutics - Boehringer Ingelheim
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Cinnamates
- Mechanism of Action Protein-serine-threonine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in USA
- 10 Nov 2015 Boehringer Ingelheim and Icahn School of Medicine, Massachusetts General Hospital, The Scripps Research Institute and Weill Cornell Medicine agree to co-develop drug for inflammatory bowel disease in USA
- 02 Sep 2008 Preclinical trials in Inflammatory bowel disease in USA (unspecified route)